# TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

- Link: https://www.thailand-business-news.com/pr-news/tempramed-signs-letter-of-intent-with-cpo-cyprus-for-exclusive-distribution-of-vivi-products-in-cyprus
- Published: 2026-09-29T14:20:00+07:00
- Author: Media OutReach

#### _Distribution partnership with one of Cyprus’s most established healthcare and consumer-products distributors_

**Highlights:**

 *  **LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI 
   Epi™ throughout Cyprus, subject to a definitive agreement.**
 *  **Proposed exclusivity is conditional on minimum annual purchase obligations,
   with combined purchases required to increase by at least 20% year over year to
   maintain exclusivity.**
 *  **Transfer pricing and the first-year minimum combined unit commitment will 
   be negotiated and established in the definitive distribution agreement.**
 *  **CPO Cyprus brings nearly a century of local market experience and established
   distribution capabilities spanning pharmaceutical products, medical instruments
   and hospital equipment.**

 Toronto, Ontario–(Newsfile Corp. – September 29, 2026) – TempraMed Technologies
Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (**“TempraMed”** or the **“Company”**),
a medical-technology innovator transforming how temperature-sensitive medications
are stored and managed, is pleased to announce that it has signed a non-binding 
letter of intent (the **“LOI”**) dated July 31, 2026 with Cyprus Pharmaceutical 
Organization Ltd. (**“CPO Cyprus”**) regarding the proposed exclusive distribution
of VIVI Cap™ and VIVI Epi™ in Cyprus.

 Under the LOI, TempraMed proposes to appoint CPO Cyprus as the exclusive distributor
of VIVI Cap and VIVI Epi in Cyprus, subject to the execution of a definitive distribution
agreement and CPO Cyprus’s compliance with minimum purchase obligations. The specific
transfer prices and first-year minimum combined unit commitment have not yet been
finalized and are to be established in the definitive agreement.

 To maintain the proposed exclusivity, CPO Cyprus would be required to increase 
its total annual combined purchases of VIVI Cap and VIVI Epi by no less than 20%
year over year. The LOI provides a 90-day period from July 31, 2026 for the parties
to negotiate and conclude a definitive agreement, unless extended by mutual agreement.

 CPO Cyprus was founded in Nicosia in 1928 and, according to CPO Group, has grown
to rank among the 20 largest trading firms in Cyprus. The company is an importer,
distributor and exclusive agent across the health, beauty, personal-care and food
sectors, with products ranging from pharmaceuticals to specialized medical instruments
and hospital equipment.

 TempraMed believes CPO Cyprus’s healthcare-market experience, established local
relationships and distribution capabilities make it a strong prospective partner
for the Company’s entry into Cyprus.

 The proposed relationship supports TempraMed’s strategy of expanding through experienced
local partners that can navigate country-specific healthcare channels and build 
sustained product adoption. If a definitive agreement is completed, Cyprus would
become an additional European market for two of TempraMed’s commercial medication-
protection products.

 _“CPO Cyprus is exactly the kind of established, market-facing partner we want 
as we expand TempraMed’s global commercial footprint,” _**said Ron Nagar, Founder
and CEO of TempraMed. **_“With roots in Cyprus dating back nearly a century and 
broad experience across pharmaceutical and medical-product distribution, CPO Cyprus
offers a strong prospective platform for introducing VIVI Cap and VIVI Epi nationwide.
The proposed annual purchase-growth requirement reflects our intention to build 
this relationship for scale. We are focused on converting this LOI into a definitive
agreement and, subject to completing that agreement and satisfying all applicable
requirements, making Cyprus another meaningful market for TempraMed. This planned
expansion further demonstrates the international relevance of our passive, battery-
free technology for people who rely on temperature-sensitive medications.”_

 **About CPO Cyprus** 
 Founded in Nicosia in 1928 as C.A. Papaellinas & Co. and
renamed Cyprus Pharmaceutical Organization in 1952, CPO Cyprus is the largest subsidiary
of CPO Group and has grown to be among the 20 largest trading firms in Cyprus. The
company operates as an importer, distributor and exclusive agent in the health, 
beauty, personal-care and food sectors. Its portfolio ranges from mass-market and
pharmaceutical products to specialized medical instruments and hospital equipment.
For more information, visit www.cpogroup.cy.

 **About TempraMed Technologies Ltd.** 
 TempraMed Technologies Ltd. is a global
medical-device company with a portfolio of innovative, temperature-controlled medication-
storage solutions. Founded with the mission to safeguard the effectiveness of life-
saving medications, TempraMed develops patented, FDA-registered thermal-insulation
devices that operate continuously without batteries or external power. Its commercial
product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™ and VIVI Med™. 
TempraMed enables patients and healthcare providers to confidently manage temperature-
sensitive medications anywhere, anytime.

 Investors interested in learning more about TempraMed are encouraged to contact
the Company at: 
 [ir@tempramed.com](https://www.thailand-business-news.com/pr-news/ir@tempramed.com)
[www.tempramed.com](https://api.newsfilecorp.com/redirect/ZEMo0sbaxz)

 **Contact:** 
 Julia Becker  Vice President, Capital Markets  T: +1 (604) 785-0850
E: [julia@tempramed.com](https://www.thailand-business-news.com/pr-news/julia@tempramed.com)

 Media: 
 Brenda Zeitlin  Vice President, Marketing  E: [brenda@tempramed.com](https://www.thailand-business-news.com/pr-news/brenda@tempramed.com)

 **Cautionary Statements** 
 THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND
DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR
HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

 This press release contains “forward-looking information” and “forward-looking 
statements” within the meaning of applicable Canadian securities legislation. Forward-
looking statements may be identified by words such as “anticipate,” “believe,” “
expect,” “intend,” “may,” “plan,” “potential,” “should,” “strategy,” “will” and 
similar expressions, or statements concerning events or conditions that may occur
in the future.

 Forward-looking statements in this press release include, without limitation, the
negotiation, execution and timing of a definitive distribution agreement with CPO
Cyprus; the terms of any such agreement, including transfer pricing, minimum purchase
obligations and the conditions of exclusivity; the appointment of CPO Cyprus as 
exclusive distributor of VIVI Cap and VIVI Epi in Cyprus; the anticipated benefits
of the proposed relationship; the Company’s strategy of expanding through local 
distribution partners and its ability to enter Cyprus and other European markets;
the addition or renewal of distribution agreements in other jurisdictions; regulatory
clearance and import requirements for the Company’s products in Cyprus; consumer
adoption of the Company’s products; and the Company’s ability to expand its commercial
presence in Cyprus.

 Forward-looking statements are based on the opinions, expectations and assumptions
of management as of the date of this press release, including assumptions that the
parties will successfully negotiate and execute a definitive distribution agreement
on terms consistent with the LOI; that CPO Cyprus will satisfy the conditions to
exclusivity; that required regulatory approvals and import clearances will be obtained;
and that demand for temperature-protection solutions for injectable medications 
will continue.

 Forward-looking statements are subject to known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially from those 
expressed or implied, including: that the LOI is non-binding and there is no assurance
that a definitive agreement will be entered into, or, if entered into, that it will
be on the terms contemplated by the LOI or within the anticipated timeframe; the
risk that the parties may be unable to agree on transfer pricing, minimum purchase
commitments or other material terms; the risk that CPO Cyprus may not meet minimum
purchase obligations or the 20% annual growth requirement, resulting in loss of 
exclusivity; regulatory approval and import requirements; competitive developments;
market acceptance; general economic conditions; geopolitical risks; and other risks
described in the Company’s public filings available on SEDAR+.

 Except as required by applicable securities laws, the Company undertakes no obligation
to update or revise publicly any forward-looking statements.

The issuer is solely responsible for the content of this announcement.

![](//track.media-outreach.com/index.php/WebView/490913/36955)

**Source** : [TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus](https://www.media-outreach.com/news/united-states/2026/09/29/490913/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://i0.wp.com/www.thailand-business-news.com/wp-content/
uploads/2025/04/media-outreach-20025.png?ssl=1)
